NASDAQ · Biotechnology

TECX (TECX) Stock

$28.03 -1.68% NASDAQ: TECX Healthcare

Valuation

MetricValue
Price$28.03
Market Cap$528.90M
P/E Ratio-7.12
P/B Ratio2.17
P/S Ratio0.00
EPS (TTM)$-4.05
52-Week High$39.53
52-Week Low$14.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-29.48%
ROA-28.35%
ROCE-33.47%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio25.70

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-16.0M$-33.0M$-45.0M$-58.0M$-84.0M
Net Profit$-9.0M$-32.0M$-43.0M$-58.0M$-74.0M
EPS$-33.36$-29.05$-11.53$-3.93$-4.05
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$33.0M$47.0M$39.0M$153.0M$261.0M
Total Liabilities$48.0M$93.0M$124.0M$12.0M$10.0M
Cash$28.0M$36.0M$29.0M$141.0M$254.0M
Borrowings$1.0M$6.0M$4.0M$3.0M$1.0M

Latest News

Tectonic Therapeutic Completes Enrollment in in Phase 2 Trial of TX45 MT Newswires · Jun 10, 2026 Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients GlobeNewswire · Jun 10, 2026 Tectonic Therapeutic Shares Rise After Raymond James Upgrade MT Newswires · May 26, 2026 Raymond James Upgrades Tectonic Therapeutic to Strong Buy From Outperform, Adjusts PT to $81 From $76 MT Newswires · May 26, 2026 Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-97.0M$-41.0M$-59.0M$-60.0M
Investing Cash Flow$-4.0M$-1.0M$-1.0M$0$0
Financing Cash Flow$0$0$0$78.0M$0
Net Cash Flow$27.0M$-97.0M$-7.0M$112.0M$113.0M
Free Cash Flow$-15.0M$-97.0M$-41.0M$-59.0M$-60.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-12.20%
Quick Ratio18.51
Interest Coverage—
Return 1Y37.91%
Return 3Y79.20%
Return 5Y-61.78%

Ownership

Insiders Held39.34%
Institutions Held74.11%
Institutions Float Held122.17%
Institutional HolderSharesReport Date
FMR, LLC2,816,4942026-03-31
TCG Crossover Management, LLC1,204,8912026-03-31
Aberdeen Group plc1,141,8242026-03-31
Blackrock Inc.860,3522026-03-31
Braidwell LP 847,1512026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%

About TECX

TECX is led by CEO Alise S. Reicin, employs 51 people, headquartered in US, publicly traded since 2018.

TECX stock trades at $28.03 with a market capitalization of $528.90M. The stock is valued at a price-to-earnings (P/E) ratio of -7.12, price-to-book of 2.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.39 and $39.53, and currently trades 29.1% below its 52-week high.

On profitability, TECX generates a return on equity (ROE) of -29.48%, return on capital employed of -33.47%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides